Poland· PL-100302703
Cholib
A simvastatin and fenofibrate product containing fenofibratum + simvastatinum, registered in Poland by Viatris Healthcare Limited. The same ATC class is registered in 10 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Simvastatin and fenofibrate is registered in 10 of 19 countries.
Countries holding a registration under ATC C10BA04 (simvastatin and fenofibrate), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Simvastatin and fenofibrate · ATC C10BA04
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
The record
At a glance
URPL (Poland)- Active substance
- Fenofibratum + Simvastatinum
- Manufacturer
- Viatris Healthcare Limited
- Country
- Poland (PL)
- ATC code
- C10BA04
- ATC class
- Simvastatin and fenofibrate
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05909991081089
- gtin05909991081096
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for simvastatin and fenofibrate.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Simvastatin and fenofibrate · interactions on record
2 records
2 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Simvastatin and fenofibrate in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaCHOLIBVIATRIS HEALTHCARE LIMITED, Dublin
- SwitzerlandCholib
- FinlandCholibViatris Healthcare Limited
- United KingdomCholib 145mg/20mg tabletsViatris UK Healthcare Ltd
- IcelandCholibViatris Healthcare Limited
- NetherlandsCholib 145 mg/20 mg filmomhulde tablettenViatris Healthcare Limited
- SwedenCholib 145 mg/20 mg Filmdragerad tablettViatris Healthcare Limited
- SpainCholib 145 mg/20 mg comprimidos recubiertos con peliculaMylan Ire Healthcare Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Cholib
- Liechtenstein · Cholib
- Norway · Cholib
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/25e0a56d-d315-454b-ab23-c88b0a28b4f7 GET /v1/drugs/25e0a56d-d315-454b-ab23-c88b0a28b4f7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "145 mg + 40 mg",
"packaging": "05909991081089 ¦ Rp ¦ EU/1/13/866/003 ¦ 86139\n10 tabl.\n05909991081096 ¦ Rp ¦ EU/1/13/866/004 ¦ 86140\n30 tabl.\nRp ¦ EU/1/13/866/006 ¦ 119625\n90 tabl.",
"substance": "Fenofibratum 145 mg + Simvastatinum 40 mg",
"common_name": "Fenofibratum + Simvastatinum",
"pl_product_id": "100302703",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about simvastatin and fenofibrate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.